The objectives ofthe Development Research Program of the DF/HCC Kidney Cancer SPORE are 1) to provide short-term funding for innovative and meritorious research projects in kidney cancer that have the potential to evolve into translational studies, 2) to fund efforts that will complement or enhance the overall scope and quality of the SPORE and 3) to ensure a continual renewal of high quality and innovative translational research within the SPORE. These projects may be investigator-initiated laboratory or clinical research, or they may be designed to create a shared resource or enhance the research infrastructure of the SPORE. The Program will rely on the infrastructure created by the Administration, Evaluation and Planning Core (Core 1) to accomplish these goals. The process will involve: 1) Identification of promising areas of translational research related to kidney cancer 2) Solicitation of high quality applications addressing these and other areas 3) Selection of worthy projects for funding -Provision of critiques to selected projects -Provision of critiques, encouragement and support for potentially worthy, unselected projects 4) Provision of funds to the selected projects 5) Evaluation of progress and accomplishments ofthe projects including the possibility of 2nd year funding and transition into full project status 6) Evaluation of the success of the Developmental Program as a whole This process has served us well in the initial SPORE funding period with four Projects in the current grant application (Projects 1, 3, 4 and 5) being based in total or in part on scientific knowledge that emerged from Developmental Projects. Results of the first funding cycle are summarized below. The specific steps in this process are described in more detail thereafter.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA101942-10
Application #
8517023
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
10
Fiscal Year
2013
Total Cost
$128,747
Indirect Cost
$29,007
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Chen, Fengju; Zhang, Yiqun; ÅženbabaoÄŸlu, Yasin et al. (2016) Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep 14:2476-89
Choueiri, Toni K; Fishman, Mayer N; Escudier, Bernard et al. (2016) Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res :
Albiges, Laurence; Hakimi, A Ari; Xie, Wanling et al. (2016) Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Clin Oncol :
Schildberg, Frank A; Klein, Sarah R; Freeman, Gordon J et al. (2016) Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity 44:955-72
de Velasco, Guillermo; Miao, Diana; Voss, Martin H et al. (2016) Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. Cancer Immunol Res 4:820-822
de Velasco, Guillermo; Krajewski, Katherine M; Albiges, Laurence et al. (2016) Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunol Res 4:12-7
Gelpi-Hammerschmidt, Francisco; Tinay, Ilker; Allard, Christopher B et al. (2016) The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. J Urol 195:399-405
Robson, Philip M; Madhuranthakam, Ananth J; Smith, Martin P et al. (2016) Volumetric Arterial Spin-labeled Perfusion Imaging of the Kidneys with a Three-dimensional Fast Spin Echo Acquisition. Acad Radiol 23:144-54
Meng, Chen; Zeleznik, Oana A; Thallinger, Gerhard G et al. (2016) Dimension reduction techniques for the integrative analysis of multi-omics data. Brief Bioinform 17:628-41
Reardon, David A; Gokhale, Prafulla C; Klein, Sarah R et al. (2016) Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res 4:124-35

Showing the most recent 10 out of 118 publications